Universe Pharmaceuticals Files 6-K Report

TL;DR

Universe Pharma (UP) filed a 6-K on 9/20 for Q1 2024, confirming 20-F filings.

AI Summary

Universe Pharmaceuticals INC filed a Form 6-K on September 20, 2024, reporting for the period ending March 31, 2024. The filing is a report of a foreign private issuer and indicates the company files annual reports under Form 20-F. The company's principal executive offices are located in Ji'an, Jiangxi, China.

Why It Matters

This filing provides an update on Universe Pharmaceuticals INC's reporting status as a foreign private issuer, which is crucial for investors tracking regulatory compliance and financial disclosures.

Risk Assessment

Risk Level: low — This is a routine regulatory filing and does not contain new financial performance data or significant corporate events.

Key Numbers

• 001-40231 — SEC File Number (Identifies the company's filing history with the SEC)

Key Players & Entities

• Universe Pharmaceuticals INC (company) — Filer of the report
• 20240920 (date) — Filing date
• 20240331 (date) — Period of report
• Ji'an, Jiangxi, China (location) — Company's principal executive offices

FAQ

Filing Documents

• ea0215125-6k_universe.htm (6-K) — 23KB
• ea021512501ex99-1_universe.htm (EX-99.1) — 592KB
• ea021512501ex99-2_universe.htm (EX-99.2) — 200KB
• ea021512501ex99-3_universe.htm (EX-99.3) — 145KB
• 0001213900-24-080675.txt ( ) — 6235KB
• upc-20240331.xsd (EX-101.SCH) — 82KB
• upc-20240331_cal.xml (EX-101.CAL) — 57KB
• upc-20240331_def.xml (EX-101.DEF) — 335KB
• upc-20240331_lab.xml (EX-101.LAB) — 543KB
• upc-20240331_pre.xml (EX-101.PRE) — 350KB
• ea0215125-6k_universe_htm.xml (XML) — 682KB

Management's Discussion and Analysis of Financial Condition and Results of Operations as Exhibit 99.2;

Management's Discussion and Analysis of Financial Condition and Results of Operations as Exhibit 99.2; (3) Interactive Data File disclosure as Exhibit 101 in accordance with Rule 405 of Regulation S-T. This current report on Form 6-K is being incorporated by reference into the Form F-3 of the Company (File No. 333-268028), declared effective by the U.S. Securities and Exchange Commission on November 15, 2022. 1 SPECIAL NOTE REGARDING

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS report with respect to the Company's current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of the Company. Forward-looking statements include, but are not limited to, those statements using words such as "believe," "expect," "plans," "strategy," "prospects," "forecast," "estimate," "project," "anticipate," "aim," "intend," "seek," "may," "might," "could" or "should," and words of similar meaning in connection with a discussion of future operations, financial performance, events or conditions. From time to time, oral or written forward-looking statements may also be included in other materials released to the public. These statements are based on management's assumptions, judgments and beliefs in light of the information currently available to it. The Company cautions investors that a number of important risks and uncertainties could cause actual results to differ materially from those discussed in the forward-looking statements, including but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the U.S. Securities and Exchange Commission. Therefore, investors should not place undue reliance on such forward-looking statements. Actual results may differ significantly from those set forth in the forward-looking statements. All such forward-looking and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. 2 EXHIBIT INDEX E

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 99.3 Press Release -- Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2024 101.INS Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). 101.SCH Inline XBRL Taxonomy Extension Schema Document. 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB Inline XBRL Taxonomy Extension Labels Linkbase Document. 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Universe Pharmaceuticals INC. Date: September 20, 2024 By: /s/ Gang Lai Gang Lai Chief Executive Officer 4

View Full Filing

View this 6-K filing on SEC EDGAR